Circadian changes direction
Thursday, 12 June, 2008
Australian biotechnology firm Circadian Technologies (ASX: CIR) is restructuring and plans to evolve from a biotech incubator to a drug development company which will specialise in cancer treatments.
Circadian has appointed a product development review group, which includes both the former head of development and the former project team leader from US biotech Amgen.
The group will oversee the company's commercialisation of cancer treatment drugs based on its VEGF inhibitors, developed by subsidiary Vegenics.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
